Key facts

AstraZeneca is a leading global research and development organisation with one of the best pipelines in the pharmaceutical industry.

AstraZeneca is one of the world's leading pharmaceutical companies.
We provide innovative, effective medicines designed to fight disease in important areas of medical need; cancer, cardiovascular, gastrointestinal, infection, neuroscience and respiratory.
Our broad product portfolio includes many world leaders and a range of high potential therapies for treating cancer: Cosudex (Bicalutamide), Arimidex (Anastrozole) and Faslodex (Fluvestrant) , gastrointestinal disease: Nexium (Esomeprazole), asthma: Symbicort (Budesonide & Eformoterol), hypertension: Atacand (Candesartan Cilexetil), high cholesterol: Crestor (Rosuvastatin Calcium), migraine: Zomig (Zolmitriptan) and schrizophrenia: Seroquel (Quetiapine Fumarate).
Our products are available in over 100 countries.
Sales in 2008 totalled $31.6 billion.
R&D investment in 2008 totalled over $5 billion.
We employ around 12,000 people in research and development at 17 R&D centres in eight countries.
We have some 6 manufacturing sites in 18 countries dedicated to ensuring we can deliver a secure, high quality, cost effective supply of our product range around the world.
We employ over 65,000 people worldwide: 51% in Europe, 32% in the Americas and 17% in Asia, Africa and Australasia.

In Australia, we are based in North Ryde, New South Wales, with offices in Victoria, Queensland, South Australia and West Australia.
AstraZeneca Australia employs more than 1000 people and is committed to being recognised as an 'Employer of Choice', providing our people with learning and development opportunities.
AstraZeneca is one of Australia's largest private sector investors in medical R&D - over $250 million in Australia in the last decade.
Currently involved in over 50 clinical trials at over 200 sites across Australia - trials involving potential new treatment for prostate cancer, lung cancer, breast and ovarian cancer.